Aardvark Therapeutics, Inc. (AARD) stock forecast and price target
Price $1.33 · data as of November 13, 2026
12-month price target
Average target$4.57
Upside / downside+243.7%
Analysts7
ConsensusHold
Low $1.50Average $4.57High $10.00
Gold marker: average target · white marker: today’s price ($1.33)
Analyst ratings
Strong buy 0Buy 4Hold 5Sell 1Strong sell 1
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.27 | −11.6% | $0 |
| Next fiscal year ends December 31, 2027 | $-2.52 | +22.8% | $0 |
| Next quarter ends December 31, 2026 | $-0.75 | +7.4% | $0 |
| Quarter after ends March 31, 2027 | $-0.64 | +35.1% | $0 |
Consensus of the analysts covering Aardvark Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.
Frequently asked questions
What is the Aardvark Therapeutics stock price target?
The average 12-month target from 7 analysts is $4.57, 243.7% above the current price of $1.33 Targets range from $1.50 to $10.00.
Is Aardvark Therapeutics a buy according to analysts?
The consensus rating is “Hold” (4 buy, 5 hold, 1 sell, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Aardvark Therapeutics expected to earn?
Analysts expect EPS of $-3.27 for the fiscal year ending December 31, 2026 and $-2.52 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.